Fairvalue-Calculator Fairvalue-Calculator
EN DE

Medeon Biodesign, Inc (6499) Fair Value & Analysis

Healthcare · TW · Market cap 7.2B TWD

Price73.00 TWD
Fair Value68.50 TWD
Upside-6.2%
Quality90/100
Evidence: Low Range 51.38 TWD – 85.63 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Medeon Biodesign, Inc (6499) currently trades at 73.00 TWD, while our model-based Fair Value estimate is 68.50 TWD — implying the stock looks roughly 6.2% overvalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Medeon Biodesign, Inc (6499) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 68.50 TWD versus a price of 73.00 TWD — about −6% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6499?
Our 21-model fair value for Medeon Biodesign, Inc is 68.50 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 73.00 TWD.
What is the quality score of 6499?
Medeon Biodesign, Inc has a Quality Score of 90/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.